Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

62.14 +0.27 (+0.44%)
Streaming Delayed Price Updated: 11:08 AM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 248,086
Open 61.92
Bid (Size) 62.14 (1)
Ask (Size) 62.15 (2)
Prev. Close 61.87
Today's Range 61.89 - 62.44
52wk Range 61.25 - 86.29
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire

Performance

YTD
-21.89%
-21.89%
1 Month
-17.52%
-17.52%
3 Month
-19.28%
-19.28%
6 Month
-20.13%
-20.13%
1 Year
-18.12%
-18.12%

More News

Read More
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
From Incyte
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales
Via Investor's Business Daily
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
Via Investor's Business Daily
Why Incyte Shares Are Falling Today
Via Benzinga
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Earnings Outlook For Incyte
Via Benzinga
Ominous Death Cross Forms On Incyte's Chart
Via Benzinga
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
From Incyte
Via Business Wire
What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks
Via Benzinga
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
From Incyte
Via Business Wire
What 13 Analyst Ratings Have To Say About Incyte
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
Via InvestorPlace
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
From Incyte and MorphoSys U.S. Inc.
Via Business Wire
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
Via Investor's Business Daily
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday
Via Investor's Business Daily
Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023
Via Benzinga
Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
From Incyte
Via Business Wire
Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.